Claudia Carlucci, MSc1, Béranger Lueza, PhD2, Astrid Foix Colonier, MSc2, Zahra Kamal, MSc3, Erik Muser, PharmD, MPH4, Dominik Naessens, PhD5, Amanda Teeple4; 1Amaris, Health Economics and Market Access, UK, London, England, United Kingdom; 2Amaris, Health Economics and Market Access, France, Paris, Ile-de-France, France; 3Amaris, Health Economics and Market Access, Canada, Toronto, ON, Canada; 4Janssen Scientific Affairs, LLC, Horsham, PA; 5Janssen Pharmaceutica NV, Beerse, Antwerpen, Belgium
Introduction: The economic burden associated with work productivity loss is substantial in patients with ulcerative colitis (UC). The objective of this study was to determine the indirect costs in US dollars associated with changes in work productivity loss (WPL) for UC patients treated with ustekinumab (UST) over a year. Methods: The Work Productivity and Activity Impairment (WPAI) questionnaire completed by patients in the UNIFI trial was used to assess the average percentage of work time missed (absenteeism) and impairment while at work (presenteeism) due to UC. Absenteeism costs per year were calculated as the product of an annual salary and percentage of work time missed, whereas presenteeism costs were calculated as the product of an annual salary, work time not missed and percentage of productivity impairment. The total cost per patient associated with WPL (absenteeism + presenteeism) was assessed at baseline and after 1 year of treatment with ustekinumab using an annual salary of $54,906, as reported by the Bureau of Labor Statistics and the Census Bureau in 2018. Results: The analysis included 206 UC patients from the UNIFI trial treated with UST 6mg/kg at induction followed by 90mg taken every 8 or 12 weeks at maintenance (UST 6-UST 90 Q8W/Q12W). Of these, 137 were treated with UST 6-UST 90 Q8W. The average total costs for a UC patient at baseline by arm were $30,716 (UST 6-UST 90 Q8W/Q12W) and $30,697 (UST 6-UST 90 SC Q8W). The average absenteeism, presenteeism and total WPL costs at baseline and week 52 are reported in Figure 1. Treatment with UST 6-UST 90 Q8W/Q12W over 1 year resulted in an estimated reduction of $17,314 in WPL costs per patient (absenteeism: $6,040; presenteeism: $11,274). A similar reduction was estimated for UST 6-UST 90 Q8W treated patients (total per patient: $15,673; absenteeism: $4,887; presenteeism: $10,786). Presenteeism accounted for 65% and 69% of the total WPL costs reduction in patients receiving UST 6-UST 90 Q8W/Q12W and UST 6-UST 90 Q8W, respectively. Discussion: UC patients treated with ustekinumab over a year experienced a reduced absenteeism and impairment while at work, which was associated with savings in WPL costs. The estimated cost reductions after 1 year of treatment with ustekinumab were over $15,000 per patient for the treatment groups assessed. The largest cost reductions were found in presenteeism compared to absenteeism.
Absenteeism, presenteeism and total WPL costs in USD estimated at baseline and week 52 for patients who received ustekinumab
Disclosures: Claudia Carlucci indicated no relevant financial relationships. Béranger Lueza indicated no relevant financial relationships. Astrid Foix Colonier indicated no relevant financial relationships. Zahra Kamal indicated no relevant financial relationships. Erik Muser: Janssen Scientific Affairs, LLC – Employee. Johnson & Johnson – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds). Dominik Naessens: Johnson & Johnson – Employee, Stockholder/Ownership Interest (excluding diversified mutual funds). Amanda Teeple: Janssen Scientific Affairs LLC – Employee. Johnson & Johnson – Stockholder/Ownership Interest (excluding diversified mutual funds).